Minimal residual disease (MRD) is of the most important factor for predicting prognosis and guiding treatment of acute lymphoblastic leukemia (ALL). In this study, we investigated the prognostic significance of leukemia-associated immunophenotypes (LAIPs) as assessment of index of MRD in 125 adult B-lineage ALL (B-ALL) patients by eight-color flow cytometry. The LAIPs could be identified in 96% and 81.6% of patients with the sensitivity of 10 À 4 and 10
INTRODUCTION
It is well known that acute lymphoblastic leukemia (ALL) is a group of heterogeneous diseases in terms of chromosome translocations or molecular genetic abnormalities, which have an important role in the leukemogenesis and risk stratification. [1] [2] [3] However, a great proportion of ALL patients lack these typical genetic abnormalities, and more importantly, minimal residual disease (MRD) has an essential role in predicting relapse and even overall survival (OS). Currently, MRD assessment is increasingly applied in clinical practice for monitoring ALL that may provide physicians enough information to intervene the planned treatment of a patient earlier with intensification of chemotherapy or allogeneic stem cell transplantation. [4] [5] [6] Quantification of clonal rearrangements of immunoglobulin/ T-cell receptor (IG/TCR) genes or fusion genes by PCR [7] [8] [9] [10] and leukemia-associated immunophenotypes (LAIPs) by multiparameter flow cytometry (MFC) [11] [12] [13] [14] [15] [16] are the most commonly used methods for MRD assessment. PCR assay has been highly standardized by several study groups and considered as the gold standard for MRD monitoring in most European trials. 8, [17] [18] [19] Recently, with the development of multi-color flow cytometry and new markers, MFC method for MRD evaluation based on LAIPs is increasingly used in the management of ALL with high applicability, sensitivity and specificity and has been regarded as an important counterpart of PCR detection. 4, 12, 13, [20] [21] [22] Eight-color flow cytometric assay in assessing MRD allows to explore the expression of more cellular antigens in one combination associating a larger number of monoclonal antibodies. In addition, as compared with the classic one (3-4 color assay), it can dramatically save samples and reagents and can also offer the possibility of increasing accuracy in population identification. 23 Furthermore, this method has recently been well standardized by the Euro Flow Consortium, which provides researchers with a practicable guideline. 24, 25 Although early MRD evaluation in induction period has been introduced to guide the treatment in most major childhood ALL protocols, 11, [26] [27] [28] [29] the value of MRD in adult ALL is not evaluated so widely as pediatric patients. [30] [31] [32] [33] [34] [35] [36] In this study, we attempted to utilize a sensitive and reliable assay for monitoring MRD by eightcolor flow cytometry. Furthermore, we attempted to address the prognostic value of MRD status using LAIPs in adult B-ALL at different time points, such as the end of induction of complete remission (CR) and one consolidation therapy.
MATERIALS AND METHODS

Patients and samples
At diagnosis, 120 out of 125 patients (96%) had at least one suitable LAIPs with 0.01% sensitivity for MRD measurement by eight-color flow cytometry. With the exclusion of 14 patients from the above 120 cases who could not achieve a CR, finally a cohort of 106 adult B-ALL patients was formed for further prognostic analysis. MRD evaluation were performed in 712 follow-up samples from the 106 cases that were obtained at the end of induction of CR and after one cycle of consolidation and then were followed up every 1-2 months if the white blood cells (WBCs) was 42 Â 10 9 /l within the first year. All of the 106 patients underwent MRD detection at the end of induction of CR and one cycle of consolidation. Then the patients were followed up if the samples were available at the time points of 1 (57 cases), 2 (25), 3 (52), 4 (58), 5 (54), 6 (38), 7 (58), 8 (56), 9 (51) and 10 (51) months after one consolidation. After CR was achieved, 33 cases were consolidated with stem cell transplantation and other 73 patients were treated with chemotherapy consolidation. The detailed baseline clinical, immunophenotypic and cytogenetic characteristics of 106 patients are shown in Table 1 .
Immunophenotypic investigation of MRD by LAIPs
Fresh heparinized whole-bone marrow (BM) samples were processed on a standard NH 4 Cl whole-blood lysing technique for immunophenotyping at diagnosis and MRD monitoring during follow-up. Briefly, the BM sample containing up to 3 Â 10 6 WBCs were incubated with a titered reagent cocktail and incubated in the dark at room temperature for 15 min, then about 2.0 ml of buffered NH 4 Cl containing 0.25% ultrapure formaldehyde (Polysciences, Warrington, PA, USA) was added and incubated at room temperature in the dark for 15 min followed by a single wash with phosphate-buffered saline containing 0.3% bovine serum albumin. If 4200 ml of BM were needed for collecting up to 3 Â 10 6 WBCs, the lysing procedure followed by a single wash would be performed before staining process. For samples where TdT and cytoplasmic (Cy) CD79a and IgM (cm) were assessed, the BM were processed using the Fix-and-Perm kit according to the manufacturer's guidelines. The information of monoclonal antibodies (mAbs) and reagents used at diagnosis are shown in Supplementary Table S1 . At least 1 Â 10 5 blast cells identified by a low expression of CD45 and low side scatter (SSC) properties were obtained, and antigenic expression on blast population was systematically analyzed by eight-color flow cytometry (LSR-II, Becton Dickinson, San José , CA, USA) at diagnosis. Subtypes of B-ALL were classified into four groups as pro-B, common-B, pre-B and mature-B ALL. LAIP was identified as a cell population that could be separated completely from its counterpart at specific stage of maturation in either normal or regenerating marrow by the patterns of antigenic expression. Four main types of aberrant phenotypes in B-ALL were defined at diagnosis for LAIPs as follows: (1) cross-lineage antigen expression, (2) asynchronous antigen expression, (3) antigen dim/strong expression, and (4) ectopic phenotypes.
Although the median number of LAIPs for each case were 4 (1-7), only the aberrant antigens expressed on majority (490%) of leukemic blasts in certain case were chosen for MRD detection. MRD was considered negative when leukemic cells were o0.01%, and, for the patients with positive MRD results, three groups of low (0.01%pMRDo0.1%), intermediate (0.1%pMRDo1.0%) and high (MRDX1.0%) levels were classified.
Sensitivity evaluation of eight-color flow cytometric assay
To examine the sensitivity of eight-color flow cytometric assay in MRD detection in B-ALL, dilution experiments were performed by adding LAIPs-positive (LAIPs þ ) cells obtained from B-ALL patient to regenerating BM sample from age-matched patients of AML with undetectable MRD after chemotherapy, in which the dilution factor ranged from 1:1, 1:10, 1:100, 1:1000, 1:10000, 1:20 000, 1:40 000, 1:80 000, 1:100 000 to 1:200 000 by volume. The BM samples from five B-ALL patients with main types of LAIPs, including major cross-lineage antigen expression and antigen dim/st expression, underwent this test. At least 2.0 Â 10 6 WBCs were acquired in dilution series of 1:10 000 to 1:200 000. The same analytical strategies as that for leukemic blasts was applied in each dilution.
Normal BM cells from 20 non-hematological malignant patients and 30 regenerating BM samples after chemotherapy were used as control to establish normal antigenic expression patterns and evaluate the background expression of LAIP combinations.
Real-time quantitative (RQ)-PCR amplification of BCR-ABL fusion gene
Total RNA was extracted from mononuclear cells using TRIzol reagent (Life Technologies, Grand Island, NY, USA), and RQ-PCR was performed using 1 mg RNA with the BCR-ABL p210/p190 KIT (Yuanqi Bio-pharmaceutical CO., LTD, Shanghai, China) according to the manufacturer's recommendations in triplicate on ABI 7500 Real Time PCR system (Life Technologies). The standardization of RQ-PCR assay was performed as in previous studies. 37, 38 The quantity of BCR-ABL transcript was calculated as a ratio of BCR-ABL copy number relative to ABL copies.
Statistical analysis
CR was defined by o5% blast cells in a regenerated BM aspirate, lack of extramedullary leukemia and peripheral blood platelet and neutrophil counts of 4100 Â 10 9 /l and 1.5 Â 10 9 /l, respectively. OS was calculated from the date of disease diagnosis to death (failure) or alive at last follow-up (censored). Relapse-free survival (RFS) was defined as the time of achieving CR to treatment failure such as relapse, death or alive in CR at last follow-up (censored). The final visiting was censored on October 2012 with a median follow-up time of 18 (4-53) months, and 65 cases (61.3%) have already relapsed. Kaplan-Meier analysis was used to calculate the distribution of OS and RFS. Log rank comparison was performed to compare the difference of survivals. Two-sided P-values o0.05 were considered statistically significant. Cox model was used for the multivariate analysis of association of potential independent prognostic factors with OS and RFS. A limited backward selection procedure was used to exclude redundant variates. All the above statistical procedures were performed with the SPSS statistical software package, version 16.0 (IBM, Newyork, NY, USA). Supplementary Table S3 .
RESULTS
Sensitivity
In this work, using eight-color flow cytometry as compared with 3-4-color panels, different mAb combinations could represent several types of aberrant immunophenotypes in one tube. At diagnosis, 120 (96%) and 102 (81.6%) out of 125 patients could reach a sensitivity of 0.01% and 0.001% for MRD measurement, respectively, when compared with normal BM cells by eight-color flow cytometry. [39] [40] [41] [42] The distribution of LAIP combinations in B-ALL samples and their background expression in normal BM are shown in Supplementary Table S2. Frequencies and distribution of LAIPs and BCR-ABL and IK6 variants in B-ALL The incidence and distribution of LAIP and molecular characteristics in 106 B-ALL patients are shown in Table 3 in detail. For comparison of LAIP and molecular abnormalities, we observed that an expression of CD66c (P ¼ 0.002), coexpression of CD66c and CD33 (P ¼ 0.001), dim expression of CD34 (P ¼ 0.021) and CD38 (Po0.001) were associated with a genotype of BCR-ABL þ ALL; a coexpression of CD66c and CD33 (P ¼ 0.024) and strong expression of CD34 (P ¼ 0.028) were related to IK6 variant of IKZF1 gene. 
and 'Normal' on the X-axis mean the original B-ALL BM sample and regenerating BM sample, respectively. The minimum MRD quantity by eight-color flow cytometric assay according to samples from numbers 1 to 5 were 0.0007, 0.0015, 0.0005, 0.0005 and 0.0008%, respectively. The data were not shown on the Figure when the number of LAIP þ blasts were o10 within 2 Â 10 6 WBCs (o0.0005%).
positive by PCR but negative by flow cytometry, of which five samples had detectable leukemic cells between 0.001% and 0.01% by flow cytometric assay. Conversely, in two samples from the same patient, MRD were 10.8% and 0.55% according to flow cytometry but 0.07% and o0.001% by PCR, respectively (as indicated by arrows in Figure 2 ). Assessing of MRD by eight-color flow cytometry in adult B-ALL X-Q Weng et al with this very low but detectable levels of leukemic blasts experienced an inferior 2-year RFS (P ¼ 0.002) and OS (P ¼ 0.071) rate to those with undetectable MRD (shown in Figures 3e and f) . No further analysis for different MRD levels in the negative group was performed after one consolidation therapy, as LAIPs were not detectable in nearly all the patients (48/49, 98.0%).
Association between dynamic MRD change and prognosis. Among the 106 patients who achieved CR, 76 patients (71.7%) presented at least one MRD-positive result during the followup within the first year of treatment, and 30 patients (28.3%) sustained in MRD-negative status. Statistical significances were observed in these two groups of patients when the 2-year RFS The 2-year RFS of the patients with MRD 0.001% to o0.01% and those with undetectable MRD at the end of induction of CR (n ¼ 38) were 37.0±14.6% and 79.1 ± 9.5%, respectively (P ¼ 0.002). (f) Patients with undetectable MRD had a better 2-year OS than those with MRD 0.001% to o0.01% at the end of induction of CR (81.7 ± 8.5% and 45.7 ± 15.5%, respectively, P ¼ 0.071), but no statistical significance was observed.
rate (Po0.001) and OS rate (Po0.001) were compared as seen in Figures 4a and b . In a similar way, 58 patients (54.7%) obtained at least one MRD-negative result in contrast to 48 (45.3%) patients never reached during the treatment of the first year. Figures 4c and d shows the statistical difference of 2-year RFS (Po0.001) and OS rate (Po0.001) between these two groups.
Multivariate analysis of MRD status and clinical factors with survival In order to explore whether the status of MRD was an independent prognostic factor for RFS and OS among adult patients with ALL, a multivariate analysis was performed with the variants, including clinical factors such as gender, age, WBC count, Hb level, platelet count, consolidation therapy, blasts percentage in BM and time to achieving CR, BCR-ABL-positive, number of LAIPs, B-ALL subtype and levels of MRD at the end of induction of CR and completion of one consolidation therapy. Univariate analysis indicated that WBC count, platelet count, late CR, consolidation therapy and MRD status at CR1 and after consolidation had association with RFS (Po0.05); MRD status at two time points had association with OS (Po0.05). Multivariate analysis showed that positive MRD status (MRD 40.01%) after induction (P ¼ 0.002) and one consolidation (Po0.001) were associated with an increased risk of relapse independently. However, only MRD-positive status after one consolidation (Po0.001) suggested an inferior OS independently. The detailed data are shown in Table 4 . DISCUSSION MRD status quantified by flow cytometric analysis has been integrated as an essential part of the algorithm of the treatment guidelines in evaluating the early treatment response and predicting outcome in pediatric patients. 43, 44 However, the correlation between MRD and prognosis in adult ALL needs further exploration. Therefore, we performed this study to establish the role of MRD status in predicting the prognosis of adult B-ALL by eight-color flow cytometric method.
In our study, linear correlation analysis showed the stability and sensitivity of this method in quantification of the leukemic cells in different dilution levels. If enough WBCs (2.0 Â 10 6 ) could be reached, the sensitivity of methodology of eight-color flow cytometry could be as high as close to 1.0 Â 10 À 5 . As shown in Figure 1 , the background clusters were o0.001% in regeneration BM according to the aberrant phenotypic features of B-ALL samples except for one patient (1.5 Â 10 À 5 ). These very low levels of noisy signal ensured the high specificity of methodology of eight-color MFC. Also, we observed that eight-color evaluation procedure could identify LAIPs in most of the patients by singletube panel with a high sensitivity (96.0% for 10 À 4 and 81.6% for 10 À 5 , respectively) in comparison to normal BM. As shown in one clinical application sample in Supplementary Figure S1 , LAIPs could be monitored precisely during treatment at 0.005% level even with shifted immunophenotypes by eight-color flow cytometry.
Four main types of LAIPs were identified at diagnosis (Table 3 ). We also observed that coexpression of CD66c and CD33 was associated with BCR-ABL fusion gene and IK6 variant of IKZF1 gene, which suggested potential genetic associations between these two molecular abnormalities, as previously reported from our group by Chen et al. Many studies proved that MRD evaluated by PCR targeting to IG/TCR rearrangement and MFC for LAIPs yielded concordant results in the vast majority of patients. 7, 45, 46 A recent study by Garand et al. 20 proved that QPCR and MFC can therefore The 2-year RFS and estimated 2-year OS rate of the patients with at least a MRD-negative result or never achieving this status during the first year were 57.6 ± 7.7% and 2.4 ± 2.4% (Po0.001), respectively, and 64.2 ± 7.2% and 14.8 ± 6.1% (Po0.001), respectively.
be comparable if properly standardized and are highly complementary. More recently, Denys et al. 12 reported that six-color MFC could significantly improve the concordance with PCR-based MRD data (88 versus 96%) and particularly improve the specificity of the MRD analysis as compared with 4-color MFC. In our study, we attempted to test the reliability and accuracy of MFC assay in MRD measurement in comparison to RQ-PCR method targeting BCR-ABL fusion gene transcripts. PCR evaluation of fusion gene transcripts reported an about 10-fold higher sensitivity (10 À 5 -10 À 6 ) than MFC, but when a cutoff level of 0.01% was used to define MRD positivity, our results showed remarkable concordance between both the methods in MRD status. In the present study, mononuclear cell by Ficoll centrifugation and whole BM by lysing procedure were performed during sample preparation of PCR and MFC, which may lead to systematically higher MRD data of RQ-PCR as compared with the flow cytometry. Interestingly, as shown in Figure 2 , two samples from the same patient indicated by arrows showed higher MRD level by flow cytometry (10.8% and 0.55%, respectively) as compared with RQ-PCR (0.07% and o0.001%, respectively), which could be explained by the fact that the leukemic cells may contain more than one genetic abnormality or this patient has complicated chromosomal translocations, as the quantification of BCR-ABL fusion gene transcripts of this case was as low as 0.18% at diagnosis while LAIPs þ blasts were 95.9%.
Although there were different cutoff values of MRD, 11, 47 we used a more popular cutoff value of o0.01% as the criteria of MRD negative. In this study, we proved that statistical significance could be reached when comparing the 2-year RFS rate (Po0.001 and Po0.001, respectively) and estimated OS rate (Po0.001 and Po0.001, respectively) between the patients with MRD-negative and -positive status at the end of induction and after one cycle of consolidation. In a hierarchical analysis of the prognosis of patients with positive MRD result, a decreased RFS and OS was observed in the patients with low, intermediate and high levels of leukemic blasts at two time points, respectively. Furthermore, in dynamic analysis of MRD change and prognosis, we had proved that maintenance of a MRD-negative status was important to the prolonging of the RFS and OS, as the patients with persistent MRD-negative results in the 1 year of treatment had a superior RFS (Po0.001) and OS (Po0.001) to those without.
Interestingly, in examining the few patients with MRD-negative status (o0.01%) who suffered from short relapse with poor OS, we found that most of such patients had a detectable low level of MRD of 0.001% to o0.01% at the end of induction. Although our results showed that patients with MRD of 0.001 to 0.01% experienced significantly higher cumulative risk of relapse and a tendency of inferior 2-year OS rate than those with undetectable MRD, more patients were needed to be enrolled to testify this supposition.
In multivariate prognostic analysis in this series of patients, we proved that MRD-positive status at the end of induction and after one consolidation were independently associated with an increased risk of relapse; on the other hand, MRD of 40.01% after one consolidation was the only factor related with OS independently. The prognostic value of BCR-ABL fusion gene in adult ALL was not obvious in our analysis, which might be caused by the wide application of tailored tyrosine kinase inhibitor treatment.
In the treatment of adult ALL, no standard guideline has been established until now, and the patients who should receive more intensive chemotherapy or early allogenetic stem cell transplantation are still uncertain, with a few exception for tailored tyrosine kinase inhibitor treatment for patients with Ph chromosome. 1, 48, 49 Due to the poor prognosis of adult ALL when compared with pediatric counterparts, a care of more patient-specific way should be considered. MRD assessing by flow cytometric analysis may provide an important parameter for guiding the next treatment as indicated in this study. Patients with o0.01% leukemic cells at the end of remission induction and after one cycle of consolidation are likely to have an excellent treatment outcome, especially for those with undetectable MRD; otherwise, early intervention with high-dose chemotherapy or other strategies should be considered.
In conclusion, our study suggests that MRD status at the end of induction and one cycle of consolidation by eight-color flow Assessing of MRD by eight-color flow cytometry in adult B-ALL X-Q Weng et al cytometry could be potentially taken as a routine index in the evaluation of the treatment response for adult patients with B-ALL. Standardization of MRD assessing method in order to compare the treatment outcome of adult ALL using different treatment protocols is warranted by further multi-centered study.
